Leerink Partnrs Forecasts Danaher's Q1 Earnings (NYSE:DHR)

Danaher Co. (NYSE:DHR - Free Report) - Research analysts at Leerink Partnrs dropped their Q1 2025 earnings per share estimates for shares of Danaher in a research note issued to investors on Wednesday, December 11th. Leerink Partnrs analyst P. Souda now forecasts that the conglomerate will post earnings of $2.02 per share for the quarter, down from their prior estimate of $2.06. The consensus estimate for Danaher's current full-year earnings is $7.50 per share. Leerink Partnrs also issued estimates for Danaher's Q2 2025 earnings at $1.88 EPS, Q3 2025 earnings at $1.86 EPS, Q4 2025 earnings at $2.46 EPS, FY2025 earnings at $8.22 EPS and FY2026 earnings at $9.22 EPS.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The firm had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same quarter in the previous year, the company posted $2.02 earnings per share. The business's revenue was up 3.1% on a year-over-year basis.

A number of other research firms have also weighed in on DHR. Evercore ISI increased their target price on shares of Danaher from $275.00 to $278.00 and gave the stock an "outperform" rating in a report on Tuesday, October 1st. Raymond James cut their price objective on Danaher from $310.00 to $300.00 and set an "outperform" rating on the stock in a research report on Wednesday, October 23rd. Wells Fargo & Company assumed coverage on Danaher in a report on Tuesday, August 27th. They set an "equal weight" rating and a $280.00 target price for the company. Royal Bank of Canada cut their price target on shares of Danaher from $333.00 to $311.00 and set an "outperform" rating on the stock in a report on Wednesday, October 23rd. Finally, TD Cowen upped their price objective on shares of Danaher from $310.00 to $315.00 and gave the stock a "buy" rating in a report on Wednesday, October 23rd. Five investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $287.95.

Danaher Trading Down 0.2 %

NYSE:DHR traded down $0.53 during midday trading on Monday, reaching $234.36. 4,474,377 shares of the stock traded hands, compared to its average volume of 2,791,944. The stock has a market capitalization of $169.27 billion, a P/E ratio of 44.83, a PEG ratio of 4.33 and a beta of 0.83. Danaher has a 12 month low of $222.53 and a 12 month high of $281.70. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. The company has a fifty day moving average of $246.92 and a 200 day moving average of $257.43.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be given a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.46%. The ex-dividend date of this dividend is Friday, December 27th. Danaher's dividend payout ratio is presently 20.61%.

Institutional Trading of Danaher

Several institutional investors have recently bought and sold shares of the company. CarsonAllaria Wealth Management Ltd. bought a new position in shares of Danaher in the second quarter worth approximately $25,000. nVerses Capital LLC purchased a new stake in Danaher during the 2nd quarter valued at $25,000. Teachers Insurance & Annuity Association of America purchased a new stake in Danaher during the 3rd quarter valued at $39,000. MidAtlantic Capital Management Inc. purchased a new position in shares of Danaher in the third quarter worth $40,000. Finally, FSA Wealth Management LLC bought a new position in shares of Danaher during the third quarter valued at $50,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.